Summary
At present, there is no universally effective drug for vitiligo therapy; there are, however, various therapeutic modalities that may be beneficial. Therapeutic regimens used to treat vitiligo include psoralens and ultraviolet A light (PUVA), topical corticosteroids, fluorouracil locally applied with skin abrasion, a variety of surgical techniques to transplant autologous melanocytes from pigmented skin to nonpigmenting areas, a new photochemotherapeutic regimen using oral khellin with UVA phototherapy, and a recently proposed treatment with oral phenylalanine in combination with UVA exposure. PUVA and topical corticosteroids are the 2 most frequently used modalities. The use of effective sunscreens with a high sun protection factor (SPF) is of help in preventing the vitiliginous areas from burning and normal skin from becoming tanned. Cosmetic camouflage is also useful to disguise the white areas of skin. Finally, depigmentation should be considered in patients with >50% cutaneous involvement who fail to respond or are unwilling to undergo treatment. The selection of patients for therapy should take into consideration the patient’s motivation, the psychological impact of the disease and the clinical presentation of vitiligo, and should weigh the risks and benefits of prolonged therapy.
Similar content being viewed by others
References
Abdel-Fattah A, Aboul-Enein MN, Wassel GM, El-Menshawi BS. an approach to the treatment of vitiligo by khellin. Dermatologica 165: 1360–140, 1982
Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis BS, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. International Journal of Dermatology 28: 545–547, 1989
Brysk MM, Newton RC, Rajaramman S, Plott T, Barlow E, et al. Autologous cultured cells as a treatment for vitiligo. Abstract. Journal of Investigative Dermatology 90: 549, 1988
Gao CM, Taboeas M, García J, González E. Estudio experimental y clínico del efecto pigmentante epidérmico del extracto placentario humano. In Melagenina: selection de trabajos de investicagión publicados y presentados en Eventos Científicos, 1976–1989, Palacio de las Convencionnes de Cuba, Havana, pp. 21–30, 1989
Cormane RH, Siddiqui AH, Westerhof W, Shutgens RBH. Phenylalanine and UVA light for the treatment of vitiligo. Archives of Dermatological Research 277: 126–130, 1985
Dawber RPR. Oral trisoralen therapy in vitiligo. British Journal of Dermatology 83: 386–390, 1970
Esterly NB (Ed.) Management of vitiligo in children (a symposium). Pediatric Dermatology 3: 498–510, 1986
Falabella R. Treatment of localized vitiligo by autologous mini-grafting. Archives of Dermatology 124: 1649–1655, 1988
Ftizpatick TB, Parrish JA, Pathak MA. Phototherapy of vitiligo (idiopathic leucoderma). In Fitzpatrick TB et al. (Eds) Sunlight and man, pp. 783–791, University of Tokyo Press, Tokyo, 1974
Freeman RG, Troll D. Photosensitization of the eye by 8-methoxypsoralen. Journal of Investigative Dermatology 53: 449–453, 1969
Fulton JE, Leyden JE, Papa C. Treatment of vitiligo with topical methoxsalen and black light. Archives of Dermatology 100: 224–229, 1969
Grimes PE, Minus HR, Chakrabarti SG, Enterline J, Halder R, et al. Determination of optimal topical photochemotherapy for vitiligo. Journal of the American Academy of Dermatology 7: 771–778, 1982
Gupta AK, Anderson F. Psoralen photochemotherapy. Journal of the American Academy of Dermatology 17: 703–704, 1987
Haider RM, Pham HN, Breadon JY, Johnson B. Micro-pigmentation for the treatment of vitiligo. Journal of Dermatologic Surgery and Oncology 15: 1092–1098, 1989
Kenney Jr JA. Vitiligo. In McDonald CJ and Scott DA (Eds) Dermatology in black patients: dermatologic clinics, Vol. 6, pp. 425–434, WB Saunders Co, London, 1988
Kenney Jr JA, Grimes PE. How we treat vitiligo. Cutis 32: 347–387, 1983
Kumari J. Vitiligo treated with topical clobetasol propionate. Archives of Dermatology 120: 631–635, 1984
Lassus A, Halme K, Eskelinen A, Ranki A, Puska P, et al. Treatment of vitiligo with oral methoxasalen and UVA. Photodermatology 1: 170–173, 1984
Lerner AB, Halaban R, Klaus S, Moellmann G. Transplantation of human melanocytes. Journal of Investigative Dermatology 89: 219–224, 1987
Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone: a retrospective study of 18 vitiligo patients and a review of the literature. British Journal of Dermatology 97: 669–679, 1977
Nordlund JJ, Halder R. Melagenina: an analysis of published and other available data. Dermatologica 181: 1–4, 1990
Ortel B, Tanew A, Hönigsmann H. Treatment of vitiligo with khellin and ultraviolet A. Journal of the American Academy of Dermatology 18: 693–701, 1988
Parrish JA, Fitzpatrick TB, Shea C, Pathak MA. Photochemotherapy of vitiligo. Archives of Dermatology 112: 1531–1534, 1976
Schulpis CH, Antoniou C, Michas T, Stratigos S. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo. Pediatric Dermatology 6: 332–335, 1989
Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated witn PUVA. Journal of Investigative Dermatology 85: 269–273, 1985
Suvanprakorn P, Dee-Ananlap S, Pongsomboom C, Klaus SN. melanocyte autologous grafting for treatment of leucoderma. Journal of the American Academy of Dermatology 13: 968–974, 1985
Tsuji T, Hamada T. Topically administered fluorouracil in vitiligo. Archives of Dermatology 119: 722–727, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Antoniou, C., Katsambas, A. Guidelines for the Treatment of Vitiligo. Drugs 43, 490–498 (1992). https://doi.org/10.2165/00003495-199243040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199243040-00005